Nasdaq20d
BioRestorative Therapies, Inc. Receives FDA IND Clearance for BRTX-100 to Treat Chronic Cervical Discogenic Pain
BRTX-100 is the first and only stem cell product candidate cleared by the FDA for evaluation in the cervical degenerative disc disease setting ... affected levels are C5/C6 and C6/C7, with ...
Nasdaq20d
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
In the meantime, we continue to advance our FDA Fast Track-designated BRTX-100 chronic lumbar disc disease (cLDD ... The commonly affected levels are C5/C6 and C6/C7, with C7 being the most ...